Accordingly, we therefore suggest that evaluating the expression of PD-L1 specifically on circulating TMPs in cancer patients who undergo radiotherapy, may serve as a possible biomarker for successful combination of radiotherapy with immune checkpoint inhibition. The gene discussed is CD274; the disease is cancer.